FAS explained the drug pricing procedure when a decision on a negotiated price is withdrawn

The Federal Antimonopoly Service (FAS Russia) published an explanation on its official web-site on the procedure for selling “Ursosan” medicine made by “PRO.MED.CS” Prague a.s. (the Czech Republic) due to withdrawing a decision on negotiated maximum ex-works prices made by the Federal Tariff Service on 7 July 2015.

On 27 May 2016 FAS for the first time withdrew a decision on a negotiated medical drug price made earlier by the Federal Tariff Service.

An economic analysis of prices for drugs containing ursodeoxyolic acid (an international Non-Proprietary Name) carried out by FAS revealed that in April 2015 the registered maximum ex-works price for “Ursosan” had increased unreasonably.

The FAS decisions formed the grounds for the Ministry of Health Care of the Russian Federation withdrawing its decision on official registration of the maximum ex-works price, excluding it form the Register from 1 June 2016. Thus, from 1 June 2016 lower prices for “Ursosan” are effective (registered on 24 March 2010).

FAS explained that under the Civil Code of the Russian Federation (Part 1 Article 4), civil acts are not retroactive and are applicable to the relations developed after the acts came into force.

FAS pointed out that “the remaining “Ursosan” capsules, 250 mg, No.10,No. 50 and No. 100, acquired by wholesale and retail companies prior to 01.06.2016, can be sold at the prices calculated based on the actual purchasing prices, and drugs purchased after 01.06.2016 must be sold in accord with the prices registered in the Price Register on 24.03.2010”.